U.S. markets open in 8 hours 59 minutes
  • S&P Futures

    3,637.50
    -23.50 (-0.64%)
     
  • Dow Futures

    29,049.00
    -154.00 (-0.53%)
     
  • Nasdaq Futures

    11,230.75
    -103.00 (-0.91%)
     
  • Russell 2000 Futures

    1,658.40
    -10.00 (-0.60%)
     
  • Crude Oil

    77.39
    -1.11 (-1.41%)
     
  • Gold

    1,632.60
    -3.60 (-0.22%)
     
  • Silver

    18.17
    -0.17 (-0.94%)
     
  • EUR/USD

    0.9559
    -0.0039 (-0.40%)
     
  • 10-Yr Bond

    3.9640
    -3.8780 (-100.00%)
     
  • Vix

    32.60
    -32.26 (-100.00%)
     
  • GBP/USD

    1.0650
    -0.0081 (-0.76%)
     
  • USD/JPY

    144.7440
    -0.0470 (-0.03%)
     
  • BTC-USD

    18,782.74
    -1,255.29 (-6.26%)
     
  • CMC Crypto 200

    429.72
    -29.42 (-6.41%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,002.33
    -569.54 (-2.14%)
     

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

·1 min read

TAMPA, Fla., Sept. 17, 2022 /CNW/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).

World's first IDE approved Sirolimus Coated Balloon in Coronary - MagicTouch SCB (PRNewsfoto/Concept Medical)
World's first IDE approved Sirolimus Coated Balloon in Coronary - MagicTouch SCB (PRNewsfoto/Concept Medical)

US FDA's IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support safety and effectiveness of this combination product. The data generated from this IDE clinical study will support a pre-market approval (PMA) application in the USA.

MagicTouch SCB is the world's first Sirolimus-coated Balloon with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. More than 100 thousand patients have been treated with MagicTouch SCB in these markets.

About MagicTouch SCB:

MagicTouch SCB is a CE marked and commercially marketed Sirolimus coated balloon developed by Concept Medical, using proprietary Nanoluté Technology. MagicTouch SCB has been used in >50,000 patients in major global markets.

About Concept Medical Inc (CMI):

CMI is headquartered in Tampa, Florida and has operational offices in The Netherlands, Singapore and Brazil and manufacturing units in India. CMI specializes in developing drug-delivery systems and has unique and patented technology platforms that can be deployed to deliver any drug / pharmaceutical agent across the luminal surfaces of blood vessels.

www.conceptmedical.com

Photo - https://mma.prnewswire.com/media/1901255/MagicTouch.jpg
Logo - https://mma.prnewswire.com/media/1244676/Concept_Medical_Logo.jpg

 

 

 

Concept Medical Logo (PRNewsfoto/Concept Medical Inc.)
Concept Medical Logo (PRNewsfoto/Concept Medical Inc.)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/magictouch-scb-receives-ide-approval-for-in-stent-restenosis-indication-301626645.html

SOURCE Concept Medical

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/17/c0944.html